This study is currently not recruiting participants.
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Not Recruiting
100 years or below
All
Phase
N/A
Brief description of study.
The purpose of this study is to compare the effects, good and/or bad of three drug combinations.
Detailed description of study
The purpose of this study is to compare the effects, good and/or bad of three drug combinations.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Leukemia
Age:
100 years or below
Gender: All
Updated on
20 Mar 2014.
Study ID: 1306011652
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
